Aligos Therapeutics, Inc. (NASDAQ:ALGS)’s share price fell 4.6% on Thursday . The company traded as low as $19.64 and last traded at $19.64. 688 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 72,093 shares. The stock had previously closed at $20.59.
A number of research firms recently weighed in on ALGS. Zacks Investment Research lowered shares of Aligos Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, March 26th. Jefferies Financial Group restated a “buy” rating and set a $42.00 price target on shares of Aligos Therapeutics in a research report on Thursday, April 1st. Finally, Piper Sandler lifted their price objective on shares of Aligos Therapeutics from $35.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, March 24th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $35.75.
The company has a fifty day simple moving average of $24.55.
Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings results on Monday, March 22nd. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.27). On average, research analysts predict that Aligos Therapeutics, Inc. will post -4.77 EPS for the current fiscal year.
A number of institutional investors have recently bought and sold shares of ALGS. Hillhouse Capital Advisors LTD. purchased a new position in shares of Aligos Therapeutics in the fourth quarter valued at about $59,864,000. Janus Henderson Group PLC purchased a new position in shares of Aligos Therapeutics in the fourth quarter valued at about $50,009,000. Baker BROS. Advisors LP purchased a new position in shares of Aligos Therapeutics in the fourth quarter valued at about $44,517,000. Pivotal bioVenture Partners Investment Advisor LLC purchased a new position in shares of Aligos Therapeutics in the fourth quarter valued at about $24,237,000. Finally, BlackRock Inc. purchased a new position in shares of Aligos Therapeutics in the fourth quarter valued at about $18,376,000.
Aligos Therapeutics Company Profile (NASDAQ:ALGS)
Aligos Therapeutics, Inc, a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB).
Further Reading: What are the most popular ETFs
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.